Regentis Biomaterials advances GelrinC cartilage repair

Regentis Biomaterials, a regenerative medicine company, is advancing its lead product GelrinC, a cell-free, off-the-shelf hydrogel for knee cartilage repair. The company is targeting an estimated $3 billion U.S. market, with approximately 470,000 annual knee cartilage repair procedures. GelrinC is designed for a single 10-minute procedure without cell harvesting or laboratory expansion, and clinical data show about 100% greater pain improvement than microfracture. Regentis has secured CE Mark approval in Europe and is conducting a Phase III clinical trial in the U.S., with plans for a PMA submission to the FDA. The company is also engaging in commercialization activities in Europe, including surgeon training and Centers of Excellence. These developments are part of a paid investor awareness campaign, and the company is positioning itself to benefit from the growing regenerative medicine sector.